EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Treatment of B-lineage non-Hodgkins lymphoma using a 213Bi-labeled anti-CD20-CHX-A-DTPA antibody conjugate



Treatment of B-lineage non-Hodgkins lymphoma using a 213Bi-labeled anti-CD20-CHX-A-DTPA antibody conjugate



Journal of Nuclear Medicine 43(5 Supplement): 116P




(PDF 0-2 workdays service: $29.90)

Accession: 035980341

Download citation: RISBibTeXText



Related references

Alpha-radioimmunotherapy of B-lineage non-hodgkins lymphoma using 213Bi-labelled anti-CD19- and anti-CD20-CHX-A-DTPA. Abstracts of Papers American Chemical Society 225(1-2): NUCL 78, 2003

Alpha-radioimmunotherapy of B-cell non Hodgkins lymphoma Preclinical evaluation of 213Bi-labeled CD19- and CD20-CHX-A-DTPA conjugates. Onkologie 23(Sonderheft 7): 47, October, 2000

Internal radiotherapy - II. Treatment of non-Hodgkins lymphoma with Y-90-labeled anti-CD20 monoclonal antibody. Radioisotopes 56(4): 197-202, 2007

Monoclonal anti-CD20 antibody rituximab for treatment of CD20-positive Hodgkins lymphoma The German experience. Blood 96(11 Part 1): 729a, November 16, 2000

ZevalinTM 90Yttrium labeled anti-CD20 , a new treatment for non-Hodgkins lymphoma. Current Pharmaceutical Biotechnology 2(4): 341-349, December, 2001

Human-mouse chimeric 131I-labeled anti-CD20 monoclonal antibody in relapsed non-Hodgkins lymphoma Dosimetry and radioimmunotherapy. Journal of Nuclear Medicine 41(5 Suppl ): 268P, 2000

Phase I study of IDEC-Y2B8 90-yttrium labeled anti-CD20 monoclonal antibody therapy of relapsed Non-Hodgkins lymphoma. Blood 86(10 SUPPL 1): 55A, 1995

Y-90 anti-CD20 monoclonal antibody dosimetry calculated from In-111 anti-CD20 in patients with low and intermediate grade B-cell non-Hodgkins lymphoma. Journal of Nuclear Medicine 38(5 SUPPL ): 251P, 1997

The anti-tumor effect of monoclonal anti-CD20 antibody therapy includes direct anti-proliferative activity and induction of apoptosis in CD20 positive non-Hodgkins lymphoma cell lines. Blood 88(10 SUPPL 1 PART 1-2): 637A, 1996

Targeted anti-cancer therapy using a chimeric anti-CD20 antibody in the treatment of non-Hodgkins B cell lymphoma. Immunology 89(SUPPL 1): 19, 1996

Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody in the treatment of non-Hodgkins B-cell lymphoma. Biochemical Society Transactions 25(2): 705-708, 1997

The monoclonal antibody anti-CD20 for the treatment of patients with low grade non Hodgkins lymphoma. Annals of Hematology 77(SUPPL 2): S26, 1998

Monoclonal anti-CD20 antibody rituximab is safe and efficient in patients with CD20-positive Hodgkins lymphoma. Onkologie 23(Sonderheft 7): 147, October, 2000

Chimeric monoclonal anti-CD20 antibody rituximab for the therapy of B-cell non-Hodgkins lymphoma Treatment results and new clinical studies. Annals of Hematology 77(SUPPL 2): S148, 1998

Preclinical evaluation of 90Y-labeled anti-CD20 monoclonal antibody for treatment of non-Hodgkin's lymphoma. International Journal of Oncology 15(5): 1017-1025, 1999